ArticleInternational journal of clinical pharmacy2015
Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future.
Article in International journal of clinical pharmacy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Article
- Improving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020.BMJ global health · 2022Article
- Availability, prices and affordability of essential medicines: A cross-sectional survey in Hanam province, Vietnam.PloS one · 2021Article
- Evaluating Price and Availability of Essential Medicines in China: A Mixed Cross-Sectional and Longitudinal Study.Frontiers in pharmacology · 2020Article
- Towards universal health coverage: achievements and challenges of 10 years of healthcare reform in China.BMJ global health · 2020Review
- Availability, prices and affordability of essential medicines in Zhejiang Province, China.PloS one · 2020Article
- Article
- The availability, price and affordability of essential antibacterials in Hubei province, China.BMC health services research · 2018Article
- Interrupted time-series analysis of the impact of generic market entry of antineoplastic products in China.BMJ open · 2018Article
- Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.BMC health services research · 2018Article
- Availability, prices and affordability of UN Commission's lifesaving medicines for reproductive and maternal health in Uganda.Journal of pharmaceutical policy and practice · 2017Article
- The availability and affordability of orphan drugs for rare diseases in China.Orphanet journal of rare diseases · 2016Article
- Use of medicines in São Paulo, Brazil, and State Health Care Coverage, 2003 and 2015.Clinics (Sao Paulo, Brazil)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2009, China implemented the National Essential Medicines System (NEMS) to improve access to high-quality low-cost essential medicines.
objectiveTo measure the prices, availability and affordability of medicines in China following the implementation of the NEMS.
setting120 public hospitals and 120 private pharmacies in ten cities in Shaanxi Province, Western China.
methodThe standardized methodology developed by the World Health Organization and Health Action International was used to collect data on prices and availability of 49 medicines.
main outcome measuresMedian price ratio; availability as a percentage; cost of course of treatment in days' wages of the lowest-paid government workers.
resultsIn the public hospitals, originator brands (OBs) were procured at 8.89 times the international reference price, more than seven times higher than the lowest-priced generics (LPGs). Patients paid 11.83 and 1.69 times the international reference prices for OBs and generics respectively. A similar result was observed in the private pharmacies. The mean availabilities of OBs and LPGs were 7.1 and 20.0 % in the public hospitals, and 12.6 and 29.2 % in the private pharmacies. Treatment with OBs is therefore largely unaffordable, but the affordability of the LPGs is generally good.
conclusionHigh prices and low availability of survey medicines were observed. The affordability of generics, but not OBs, is reasonable. Effective measures should be taken to reduce medicine prices and improve availability and affordability in Shaanxi Province.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.